$5.31
6.63% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US19240Q2012
Symbol
COGT
Sector
Industry

Cogent Biosciences Inc Stock price

$5.31
+1.01 23.49% 1M
-3.77 41.52% 6M
-2.49 31.92% YTD
-2.53 32.27% 1Y
+0.58 12.26% 3Y
+3.19 150.52% 5Y
-39.13 88.05% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.33 6.63%
ISIN
US19240Q2012
Symbol
COGT
Sector
Industry

Key metrics

Market capitalization $604.58m
Enterprise Value $484.18m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 5.46
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-288.47m
Free Cash Flow (TTM) Free Cash Flow $-222.82m
Cash position $245.66m
EPS (TTM) EPS $-2.38
P/E forward negative
Short interest 15.10%
Show more

Is Cogent Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Cogent Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Cogent Biosciences Inc forecast:

9x Buy
75%
3x Hold
25%

Analyst Opinions

12 Analysts have issued a Cogent Biosciences Inc forecast:

Buy
75%
Hold
25%

Financial data from Cogent Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs 4.47 4.47
14% 14%
-
-4.47 -4.47
14% 14%
-
- Selling and Administrative Expenses 41 41
24% 24%
-
- Research and Development Expense 239 239
28% 28%
-
-284 -284
27% 27%
-
- Depreciation and Amortization 4.47 4.47
14% 14%
-
EBIT (Operating Income) EBIT -288 -288
27% 27%
-
Net Profit -270 -270
27% 27%
-

In millions USD.

Don't miss a Thing! We will send you all news about Cogent Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cogent Biosciences Inc Stock News

Neutral
GlobeNewsWire
15 days ago
Three Registration-Directed Top-line Data Readouts Remain on Track in 2025: SUMMIT in NonAdvanced SM expected in July, APEX in Advanced SM expected in second half of the-year and PEAK in GIST expected by end of year Ended 1Q 2025 with $245.7 million in cash, sufficient to fund operations into late 2026 WALTHAM, Mass. and BOULDER, Colo.
Neutral
GlobeNewsWire
about 2 months ago
Four abstracts accepted for poster presentation highlight Cogent's expertise in pioneering best-in-class therapeutics Four abstracts accepted for poster presentation highlight Cogent's expertise in pioneering best-in-class therapeutics
More Cogent Biosciences Inc News

Company Profile

Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. The firm’s technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.

Head office United States
CEO Andrew Robbins
Employees 205
Founded 2014
Website www.cogentbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today